Moreover, LY294002 enhances AKT phosphorylation in gemcitabine-resistant pancreatic cancer cells by partially occupying the PI3K active site, which may inadvertently activate other signaling pathways [44]. The gene discussed is AKT1; the disease is pancreatic neoplasm.